Phase 1 trial of chlorozotocin

R. J. Gralla, C. T.C. Tan, C. W. Young

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Chlorozotocin was given to 37 patients with advanced malignant tumors in a daily x 5 schedule at 6-week intervals. Total iv doses for each course ranged from 75 to 200 mg/m2. Myelosuppression was dose-limiting, with a platelet count depression regularly observed at doses of ≥ 150 mg/m2; leukopenia occurred only at the highest dose level. Nausea and vomiting were mild and uncommon. No hyperglycemia or adverse drug-related effects in renal or hepatic function were observed. No major antitumor activity occurred; however, three patients with renal cell carcinoma and one patient each with lung cancer, ovarian carcinoma, and Hodgkin's disease had minor objective decreases in tumor size. A dose range of 150-200 mg/m2 iv for each 5-day course is recommended for phase II studies.

Original languageEnglish (US)
Pages (from-to)17-20
Number of pages4
JournalCancer Treatment Reports
Issue number1
StatePublished - 1979
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase 1 trial of chlorozotocin'. Together they form a unique fingerprint.

Cite this